ISPOR - PCN53 Cost-Utility Analysis of Dacomitinib As First-LINE Treatment for Patients with Locally Advanced or Metastatic NON-SMALL CELL LUNG Cancer in China

PCN53 Cost-Utility Analysis of Dacomitinib As First-LINE Treatment for Patients with Locally Advanced or Metastatic NON-SMALL CELL LUNG Cancer in China

Abstract

Authors

J. Zhao L. Yang G. Jin

Full Text Cite This Article

Back to Volume 22, Supplemental S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now